Best of the Poster Sessions

Poster Session 01: Using all we have or wait - modern management of metastatic RCC

Friday 16 March 2018
09:00 - 10:30

Green Area, Room 2 (Level 0)

1 Surgical safety of immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. Data from the EORTC randomized trial 30073 SURTIME

Bex A. 1 , Mulders P. 2 , Jewett M. 3 , Wagstaff J. 4 , Van Velthoven R. 5 , Laguna P. 6 , Wood L. 7 , Van Melick H. 8 , Soetekouw P. 9 , Lattouf J. 10 , Powles T. 11 , De Jong I. 12 , Rottey S. 13 , Tombal B. 14 , Marreaud S. 15 , Collette S. 15 , Collette L. 15 , Haanen J. 16

11 Statins and prognosis of renal cell cancer: A retrospective Finnish cohort study

Eskelinen T. 1 , Tammela T. 2 , Kotsar A. 3 , Murtola T. 2

Poster Session 02: How to improve preoperative workup and surgical management of adrenals and retroperitoneal tumours?

Friday 16 March 2018
09:00 - 10:30

Blue Area, Room 2 (Level 0)

15 MECA-79-positive high endothelial venule density may associate with pheochromocytoma aggressiveness

Yasuhiro H., Yoneyama T., Yamamoto H., Hatakeyama S., Imai A., Yoneyama T., Koie T., Ohyama C.

17 Perioperative imaging techniques and immunohistochemistry to investigate the feasibility of laparoscopic partial adrenalectomy in primary aldosteronism

Van de Wiel E. 1 , Küsters B. 2 , Veltien A. 3 , Mann R. 3 , Mukai K. 4 , Deinum J. 5 , Langenhuijsen J. 1

Poster Session 03: Penile cancer - a rare disease demands expert treatment

Friday 16 March 2018
09:00 - 10:30

Blue Area, Room 5 (Level 0)

26 Tumour escape in the microenvironment of penile squamous cell carcinoma; immune factors and clinicopathological predictors of lymph node metastasis and disease specific survival

Ottenhof S. 1 , Djajadiningrat R. 2 , Thygesen H. 3 , Jakobs P. 1 , Józwiak K. 4 , Heeren A. 5 , De Jong J. 6 , Sanders J. 6 , Horenblas S. 1 , Jordanova E. 5

28 Relevance of HPV-status and histopathology for prognosis and miRNA expression in patients with penile carcinoma

Hölters S. 1 , Heinzelmann J. 1 , Khalmurzaev O. 2 , Matveev V. 2 , Loertzer P. 1 , Ueberdiek S. 1 , Janssen M. 1 , Pfuhl T. 3 , Smola S. 3 , Bohle R. 4 , Pryalukhin A. 5 , Fuhrich N. 6 , Geppert C. 6 , Hartmann A. 6 , Loertzer H. 7 , Hauschild E. 8 , Wunderlich H. 9 , Schöpe J. 10 , Wagenpfeil S. 10 , Stöckle M. 1 , Junker K. 1

Poster Session 04: Renal tumours: Novel approaches to overcome therapy resistance

Friday 16 March 2018
10:45 - 12:15

Red Area, Room 1 (Level 0)

38 Effect of a ketogenic diet on the clear cell renal cell carcinoma cell growth

Benoit M. 1 , Fortier E. 1 , Barth M. 2 , Procaccio V. 2 , Bourreau J. 3 , Henrion D. 3 , Bigot P. 1

39 Bromodomain protein BRD4 inhibition as a novel therapeutic approach in sunitinib-resistant renal cell carcinoma

Sakaguchi T., Yoshino H., Sugita S., Osako Y., Yonemori M., Miyamoto K., Nakagawa M., Enokida H.

Poster Session 05: Prostate cancer metabolic alterations

Friday 16 March 2018
10:45 - 12:15

Blue Area, Room 2 (Level 0)

56 Diabetes associated alterations of the androgen receptor signaling pathway in patients with prostate cancer

Todenhöfer T.W. 1 , Lutz S.Z. 2 , Hennenlotter J. 1 , Lehmann R. 2 , Scharpf M. 3 , Kantartzis K. 2 , Sailer C. 4 , Fritsche L. 4 , Schmid V. 4 , Berti L. 4 , Peter A. 2 , Staiger H. 4 , Fritsche A. 2 , Stenzl A. 1 , Häring H-U. 2 , Heni M. 2

57 Genomic analysis of primary high-risk prostate cancer tumors with metastatic recurrence identifies antizyme inhibitor 1 as a regulator of cancer cell migration through regulation of collagen expression

Van Den Broeck T. 1 , Moris L. 1 , Gevaert T. 1 , Prekovic S. 2 , Tosco L. 1 , Smeets E. 2 , Lehrer J. 3 , Haddad Z. 3 , Helsen C. 2 , Margrave J. 3 , Boeckx B. 4 , Lambrechts D. 4 , Van Poppel H. 1 , Everaerts W. 1 , Chellisery J. 3 , Erho N. 3 , Buerki C. 3 , Davicioni E. 3 , Joniau S. 1 , Claessens F. 2

Poster Session 06: Survivorship in prostate cancer: It is all about patients

Friday 16 March 2018
10:45 - 12:15

Blue Area, Room 5 (Level 0)

64 Can active surveillance really reduce the harms of overdiagnosing prostate cancer? A reflection of real life clinical practice in the PRIAS study

Drost F.J. 1 , Bangma C. 2 , Kakehi Y. 3 , Pickles T. 4 , Rannikko A. 5 , Valdagni R. 6 , Roobol M. 2 , the PRIAS study group7

68 Patients with urological malignancy are 5 times more likely to commit suicide: A large national cohort study

Afshar M. 1 , Bardoli A.D. 2 , Tanner J-R. 3 , Macfarlane N. 4 , Pickering L. 4 , Anderson C. 4 , Evison F. 3 , Patel P. 2

Poster Session 07: Renal tumours: Heterogeneity, molecular pathology and biomarkers

Friday 16 March 2018
12:30 - 14:00

Red Area, Room 1 (Level 0)

79 Absolute copy number and fragments size of circulating cell-free DNA are useful markers for renal cell carcinoma

Uemura M. 1 , Yamamoto Y. 1 , Nakano K. 1 , Hayashi Y. 1 , Wang C. 1 , Ishizuya Y. 1 , Matsuzaki K. 1 , Hayashi T. 1 , Kinouchi T. 1 , Jingushi K. 2 , Kato T. 1 , Kawashima A. 1 , Nagahara A. 1 , Fujita K. 1 , Nonomura N. 1

84 Prognostic impact of tumor-infiltrative lymphocytes and circulating cytokines in patients undergoing radical nephrectomy for localized renal cell carcinoma

Iida K., Miyake M., Onishi K., Hori S., Morizawa Y., Gotoh D., Tatsumi Y., Onishi S., Nakai Y., Anai S., Tanaka N., Fujimoto K.

Poster Session 08: Evolving systemic treatment of urothelial cancer

Friday 16 March 2018
12:30 - 14:00

Blue Area, Room 1 (Level 0)

87 Adjuvant immunotherapy after cystectomy for MIBC patients: Lessons learned from the phase II clinical trial ‘Magnolia’

Mulders P.F.A. 1 , Colombel M. 2 , Heidenreich A. 3 , Martínez-Piñeiro L. 4 , Babjuk M. 5 , Korneyev I. 6 , Surcel C. 7 , Yakovlev P. 8 , Radziszewski P. 9 , Colombo R. 10 , Witjes J.A. 1 , Caris C. 11 , Schipper R. 11 , Witjes W.P.J. 11 , EAU Research Foundation Magnolia Group12

89 Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma

Necchi A. 1 , Mariani L. 2 , Lo Vullo S. 2 , Raggi D. 1 , Giannatempo P. 1 , Bamias A. 3 , Crabb S. 4 , Bellmunt J. 5 , Yu E. 6 , Niegisch G. 7 , Vaishampayan U. 8 , Theodore C. 9 , Berthold D. 10 , Srinivas S. 11 , Sridhar S. 12 , Plimack E. 13 , Rosenberg J. 14 , Powles T. 15 , Galsky M. 16 , Sonpavde G. 17

Poster Session 09: Novel biomarkers for prostate cancer: The research continues

Friday 16 March 2018
12:30 - 14:00

Blue Area, Room 2 (Level 0)

99 CHD1 deletion is an independent predictor of poor prognosis by increased metastasis in both PTEN-deficient and -intact prostate cancer

104 Potential new minimally-invasive diagnostic biomarkers for prostate cancer

Bjerre M.T. 1 , Strand S. 1 , Fredsøe J. 1 , Høyer S. 2 , Mortensen M. 3 , Borre M. 3 , Sørensen K. 1

Poster Session 10: Laser treatment of benign prostatic obstruction: Moving forward

Friday 16 March 2018
12:30 - 14:00

Blue Area, Room 3 (Level 0)

116 Low power vs. high power holmium laser enucleation of the prostate: Critical assessment through randomized trial

Elshal A., El-Nahas A., Ghazy M., Nabeeh H., Abolazm A., El-Kappany H.

122 Perioperative major acute cardiovascular events after 180-watt Green Light laser photoselective vaporization

Marchioni M. 1 , Cindolo L. 2 , De Nunzio C. 3 , Greco F. 4 , Destefanis P. 5 , Bergamaschi F. 6 , Ferrari G. 7 , Fasolis G. 8 , Palmieri F. 9 , Divan C. 10 , Oriti R. 11 , Ruggera L. 12 , Tubaro A. 3 , Dadone C. 13 , De Rienzo G. 14 , Frattini A. 15 , Mirone V. 4 , Ricciardulli S. 6 , Varvello F. 8 , Voce S. 16 , Malossini G. 10 , Tuccio A. 11 , Chiodini P. 17 , Ditonno P. 18 , Campobasso D. 15 , Schips L. 19